Costs of fluoroquinolone resistance in clinical E. coli: a potential explanation for similarities in resistance between the UK and Canada

BBSRC：罗茜三叶草：BB/M011208/1某些细菌抵抗抗生素作用的能力（抗生素耐药性）已成为一个广泛的全球健康问题。了解在没有抗生素的情况下抗生素耐药性对细菌生长的影响至关重要。以前的研究表明，在没有抗生素的情况下，耐药性会减少细菌的生长，这导致了一个被广泛接受的概念，即减少抗生素治疗将减少耐药性细菌的出现和传播。然而，这项研究的大部分是在实验室生物体上进行的。为了了解减少抗生素治疗是否是一种有效的策略，这些机制需要在临床生物中考虑。为了解决目前的研究空白，我们将研究临床大肠杆菌对常用抗生素（氟喹诺酮类）的耐药性的影响。氟喹诺酮类药物的使用在加拿大和英国不同。加拿大倾向于使用氟喹诺酮作为尿路感染的常用治疗方法，而英国则优先选择其他抗生素类别。然而，氟喹诺酮类药物的耐药率是相似的，因此还不清楚氟喹诺酮类药物处方是否会影响耐药率。在常见的实验室微生物中，氟喹诺酮耐药性与细菌生长的广泛减少有关。然而，耐药对实验室微生物和临床微生物生长的影响差异可能解释了为什么尽管处方率不同，但临床微生物的耐药率相似。如果氟喹诺酮耐药性在没有抗生素的情况下不会减少临床微生物的生长，这可能有助于解释为什么加拿大和英国的耐药率相似，尽管他们的处方药不同。

BBSRC : Rosie Clover : BB/M011208/1 The ability of some bacteria to counteract the effects of antibiotics (antibiotic resistance) has become an extensive global health issue. Understanding the effects of antibiotic resistance on bacterial growth in the absence of antibiotics is vital. Previous research has suggested that resistance reduces bacterial growth in the absence of antibiotics, leading to the widely accepted concept that suggest a reduction in antibiotic therapies will reduce the emergence and spread of resistant bacteria. However, the majority of this research has been conducted on laboratory organisms. To understand whether reducing antibiotic therapies is an effective strategy, these mechanisms need to be considered in clinical organisms.To address the current gap in research, we will study the effects of resistance to a commonly-prescribed class of antibiotics (fluoroquinolones) in clinical Escherichia coli. Use of fluoroquinolones differs between Canada and the UK. Canada tends to use fluoroquinolone as a common treatment for urinary tract infections, whereas the UK preferentially opts for other antibiotic classes. Yet the rates of fluoroquinolone resistance are similar, making it unclear whether the fluoroquinolone prescribing influences the rate of resistance. In common laboratory organisms, fluoroquinolone resistance is associated with extensively reduced bacterial growth. However, differences in the effects of resistance on growth between laboratory organisms and clinical organisms may explain why resistance rates in clinical organisms are similar despite different rates of prescription. If fluoroquinolone resistance does not reduce the growth of clinical organisms in the absence of antibiotics, this could help to explain why rates of resistance in Canada and the UK are similar despite their different prescribing practises.